Consumer Commitment Code
The following principles constitute the Personal Care Products Council’s Consumer Commitment Code:
- A company should market cosmetics products only after ensuring every ingredient and finished product has been substantiated for safety. The decision that an ingredient has been substantiated for safety may be based on a finding by the Cosmetic Ingredient Review (CIR) Expert Panel that such ingredient is safe for the intended use or on other appropriate data and information.
- When marketing a cosmetics product containing an ingredient that exceeds the concentration or applications reviewed by the CIR Expert Panel, or for which the CIR Expert Panel has found the “Use Not Supported by the Data and Information Submitted to the CIR,” a company should possess information sufficient to substantiate the safety of the ingredient as used in such product and be willing to make that information available for inspection by the FDA.
- When marketing a cosmetics product containing an ingredient identified as a “fragrance,” a company should disclose the presence of internationally recognized contact allergens identified in, and in conformance with, PCPC’s “Voluntary Fragrance Ingredient Disclosure Guideline.”
- A company should participate in the applicable parts of the FDA Voluntary Cosmetic Reporting Program (VCRP) set forth in 21 CFR Parts 710 and 720 for products marketed in the United States, and file timely reports regarding its manufacturing establishments and ingredient usage.
- Although serious and unexpected adverse events are extremely rare for cosmetics products, a company should notify the FDA of any known serious and unexpected adverse event as a result of the use of any of its cosmetics products marketed and used in the United States.
- A company should maintain a safety information summary of ingredient and product safety information and data regarding its cosmetics products marketed in the United States as specified in PCPC’s Safety Information Summary Program Guideline, and make any information in that safety information summary available for inspection by FDA under the conditions specified in that program.
* * * *